10012- MPC-2 DIFFERENCE BETWEEN HISTOLOGICAL AND INTEGRATED DIAGNOSES; IMPLICATIONS FOR TREATMENT

Akira Kurose, Kenichiro Asano, Akihisa Kamataki, Runa Nakagawa, Akane Hirayama · 2024

Read 10012- MPC-2 DIFFERENCE BETWEEN HISTOLOGICAL AND INTEGRATED DIAGNOSES; IMPLICATIONS FOR TREATMENT by Akira Kurose, Kenichiro Asano, Akihisa Kamataki, Runa Nakagawa, Akane Hirayama (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605596.txt.

Description

Akira Kurose and co-authors compare, in 2024, two ways of diagnosing gliomas: the microscope alone versus the modern integrated diagnosis that adds molecular tests. Molecular analysis is available at few centers, so many treatment choices still rest on appearance. The team reclassified seventy glioma cases both ways.

Sixty-five cases landed in the same place under both systems. Five patients, though, jumped from grade two or three to grade four once molecular results were added, a change big enough to alter treatment. The authors argue molecular testing should widen, and that sampling more of the tumor helps the microscope diagnosis approach the integrated one.

Catalog record

CREATORAkira Kurose, Kenichiro Asano, Akihisa Kamataki, Runa Nakagawa, Akane Hirayama
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11605596

Browse the full library · About the Tower of Babel